AbbVie trims 2026 adjusted EPS guidance to $13.76-$13.96 on $216M Q3 IPR&D charge

AbbVie Inc.

Q3 2026 adjusted diluted EPS guidance cut to $3.73-$3.77 from $3.84-$3.88 after $216M pre-tax acquired IPR&D and milestones expense ($0.11/share).
Full-year 2026 adjusted diluted EPS guidance lowered to $13.76-$13.96 from $13.87-$14.07, reflecting the same $0.11 Q3 impact.
FY2026 acquired IPR&D and milestones expense now $1,251M versus $1,035M previously announced; AbbVie excludes any beyond-Q3 amounts as not reliably forecastable.
Results for the quarter ended September 30, 2026 are not finalized and remain subject to financial statement closing procedures; final figures may differ.
CFO Scott T. Reents signed the October 5, 2026 report; guidance detail is in Exhibit 99.1.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.